• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives

Introduction to 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide (CAS No. 1001757-40-9)

3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. With the CAS number 1001757-40-9, this compound represents a unique structural motif that combines a benzohydrazide moiety with a pyrazole ring substituted at the 4-position with a bromine atom and at the 3 and 5 positions with methyl groups. Such structural features make it a promising candidate for further exploration in drug discovery, particularly in the development of novel therapeutic agents targeting various biological pathways.

The benzohydrazide group is well-known for its utility in medicinal chemistry due to its ability to form stable hydrogen bonds and participate in coordination interactions with biological targets. This functional group has been extensively studied for its pharmacological properties, including antitumor, anti-inflammatory, and antimicrobial activities. In contrast, the pyrazole scaffold is another pharmacophore that has demonstrated significant potential in drug development. Pyrazoles are heterocyclic compounds that exhibit a wide range of biological activities, such as antiviral, antifungal, and anti-inflammatory effects. The combination of these two motifs in 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide suggests that it may possess enhanced biological activity compared to individual components.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding affinity and mode of interaction of small molecules with biological targets more accurately. This has facilitated the rational design of compounds like 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide to optimize their pharmacological properties. For instance, studies have shown that the bromine substituent at the 4-position of the pyrazole ring can enhance binding interactions with certain enzymes and receptors, thereby improving drug efficacy. Similarly, the methyl groups at the 3 and 5 positions contribute to steric hindrance and electronic modulation, which can fine-tune the compound's pharmacokinetic profile.

In vitro studies have begun to elucidate the potential biological activities of 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide. Initial experiments have revealed promising results in terms of inhibitory effects on key enzymes involved in inflammatory pathways. Specifically, this compound has shown potential as an inhibitor of cyclooxygenase (COX) enzymes, which are crucial in mediating pain and inflammation. The benzohydrazide moiety is thought to interact with the active site of COX enzymes through hydrogen bonding and hydrophobic interactions, leading to reduced enzyme activity. Furthermore, preliminary data suggest that 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide may also exhibit inhibitory effects on other inflammatory mediators such as lipoxygenase and inducible nitric oxide synthase (iNOS).

The structural versatility of 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide also makes it an attractive scaffold for further derivatization. By modifying various functional groups within the molecule, researchers can explore new analogs with enhanced potency or selectivity. For example, replacing the bromine atom at the 4-position of the pyrazole ring with other halogen atoms or alkyl groups could alter electronic properties and binding interactions. Similarly, introducing additional substituents into the benzhydrazide moiety could fine-tune solubility and metabolic stability.

One particularly intriguing aspect of this compound is its potential application in targeted therapy strategies. The pyrazole scaffold has been shown to selectively interact with certain cancer cell lines due to its ability to modulate intracellular signaling pathways. For instance, studies have demonstrated that pyrazole derivatives can inhibit tyrosine kinases involved in cancer cell proliferation and survival. By incorporating this motif into 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide, researchers hope to develop novel agents that can selectively target cancer cells while minimizing toxicity to healthy tissues.

The synthesis of 3-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)methylbenzohydrazide involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Key steps include condensation reactions between appropriately substituted benzhydразides and halogenated pyrazoles under controlled conditions. Advances in synthetic methodologies have enabled more efficient production processes for such complex molecules.

Future research on 3-(4-bromo-3,5-dimethyl-1H-pyразол -1 -ы l)methylbenzohydразиде will likely focus on preclinical studies to evaluate its safety profile and therapeutic efficacy. Animal models will be employed to assess pharmacokinetic parameters such as absorption distribution metabolism excretion (ADME) properties as well as toxicological effects at various doses levels

• 17607-80-6(1-Benzyl-5-methyl-1H-pyrazole-3-carboxylic Acid)
• 134947-25-4(1-Benzoyl-3,5-bis(trifluoromethyl)pyrazole)
• 1141-70-4(1-Benzyl-3-methyl-1H-pyrazole-5-carboxylic Acid)
• 108132-57-6(Methanone,(3,5-dimethyl-1H-pyrazol-1-yl)(3,4,5-trimethoxyphenyl)-)
• 108132-58-7(Methanone,1,3-benzodioxol-5-yl(3,5-dimethyl-1H-pyrazol-1-yl)-)
• 100957-85-5(SORT-PGRN interaction inhibitor 1)
• 108444-25-3(1-benzyl-3,5-dimethyl-1H-pyrazole-4-carboxylic acid)
• 17607-81-7(Ethyl 1-Benzyl-5-methyl-1H-pyrazole-3-carboxylate)
• 108132-59-8(Methanone,(3,5-dimethyl-1H-pyrazol-1-yl)(4-ethoxy-3,5-dimethoxyphenyl)-)
• 197079-02-0(1-Methyl-1H-pyrazole-5-carbohydrazide)